New combo shows promise against tough lymphoma
Disease control
Not yet recruiting
This study tests whether adding the drug golidocitinib to standard chemotherapy and immunotherapy works better for advanced NK/T-cell lymphoma. About 40 adults with newly diagnosed, advanced disease will be split into two groups: one gets the new combo, the other gets standard tr…
Phase: PHASE2 • Sponsor: WEI XU • Aim: Disease control
Last updated May 17, 2026 17:07 UTC